Loading
A phase 2 trial of Bevacizumab, FOLFIRI in colorectal cancer, run by Oncolytics Biotech, now recruiting.
FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer is a phase 2 interventional study registered as NCT07446322 by Oncolytics Biotech, with 60 participants planned, started 2026-04-30 and due to reach its primary completion in 2027-08-30. Interventions recorded: Bevacizumab, FOLFIRI, Pelareorep. Conditions listed: Ras-mutated Metastatic Colorectal Cancer, mCRC, MSS Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Anti-angiogenic therapy, Monoclonal antibodies, Colorectal cancer.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Bevacizumab, Anti-angiogenic therapy, Colorectal cancer.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Bevacizumab, Colorectal cancer.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Monoclonal antibodies, Colorectal cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/